About Verisante
Verisante is a company based in Vancouver (Canada) founded in 2006. Verisante offers products and services including Reverse Takeover Service and Capital Raising Assistance. Verisante operates in a competitive market with competitors including Castle Biosciences, DermTech, DermaSensor, MedLumics and SciBase, among others.
- Headquarter Vancouver, Canada
- Stage Public
- SectorsHealthcare
- Website verisante.com
- Social LinkedIn X Facebook
- Legal Name Verisante Technology, Inc.
- Net Profit$22.82 K (USD)0as on Dec 31, 2025
- EBITDA-$84.55 K (USD)-0.86as on Dec 31, 2025
- Latest Funding Round$98.58K (USD), Post-IPO
Jun 2022
Products & Services of Verisante
Verisante offers a comprehensive portfolio of products and services, including Reverse Takeover Service and Capital Raising Assistance.
Facilitates mergers for companies to go public quickly.
Helps businesses secure funding for growth initiatives.
Funding Insights of Verisante
- Total Rounds 2
- Last Round Post-IPO — $98,580
- First Round $1.1M
(Nov 2013)
All 2 funding rounds of Verisante with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $98,580 | Post-IPO | – | – | – |
| Nov 2013 | $1.1M | Post-IPO | – | – | – |
IPO & Listings of Verisante
Verisante is a publicly listed company on the TSXV with ticker symbol VER.H in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Dec 2009
- Listed onTSX-V: VRS
- Listed entityVerisante Technology, Inc.
- Exchange sectorHealth technology
- ISINCA92346G2036
- Share price0.01 CAD · 2026-10-06
- Market capitalisation659,070.00 CAD
- Price to earnings8.8
- EPS (diluted, trailing year)0.00 CAD
- Volume (last session)1,000
Financials of Verisante
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | 31,240 CAD | -115,760 CAD |
| 2024 | – | -114,770 CAD | -114,770 CAD |
| 2023 | – | -90,530 CAD | -136,270 CAD |
| 2022 | – | 1.2M CAD | -287,990 CAD |
| 2021 | – | -192,250 CAD | -192,250 CAD |
Detailed financial statements for Verisante
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Verisante
4 dated milestones of Verisante across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Verisante is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.1M.
- Funding Latest funding round, Post-IPO, of $99K.
Competitors of Verisante
Verisante operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Castle Biosciences, DermTech, DermaSensor, MedLumics and SciBase, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| dermtech.com | 1996 | San Diego, United States | $24.37M | 259 | Adhesive patch biopsies for skin cancer detection are provided. | |
| dermasensor.com | 2009 | Miami, United States | $60.75M | 13 | Handheld diagnostic device for skin cancer lesions is developed. | |
| medlumics.com | 2009 | Madrid, Spain | $62.81M | – | Biological tissue imaging is developed using optical coherence tomography. | |
| scibase.com | 1998 | Stockholm, Sweden | $22.3M | – | Point-of-care device for malignant melanoma detection is provided. | |
| amlo-biosciences.com | 2017 | Newcastle Upon Tyne, United Kingdom | $7.69M | 11 | Prognostic tests for early-stage melanoma detection are developed. | |
| damae-medical.com | 2014 | Paris, France | $8.98M | – | Non-invasive 3D imaging devices for skin cancer diagnostics are developed. | |
| vivosight.com | 2006 | Maidstone, United Kingdom | $8.9M | 8 | Optical coherence tomography devices for dermatological diagnostics are provided. | |
| haut.ai | 2017 | Tallinn, Estonia | $2.15M | 4 | SaaS solutions using AI for skincare businesses are provided. | |
| veriskin.com | 2014 | San Diego, United States | $1.68M | – | Tools for non-invasive skin cancer diagnosis are developed. |
Detailed competitors of Verisante
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Verisante
Complete news archive for Verisante
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Verisante
10 companies that operate in the same segment as Verisante (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Verisante
Verisante was founded in 2006 and raised its 1st funding round 7 years after it was founded.
Verisante is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Verisante is focused on the development and commercialization of diagnostic devices for early cancer detection. The companys products Verisante Aura allows skin cancer detection and the Verisante Core series is for lung, colon, and cervical cancer detection that utilizes a proprietary cancer detection platform while the operating software and probe technology are unique to each device. Verisante Aura is a non-invasive Raman spectroscopy system designed to detect skin cancer. The system provides information by identifying spectral changes associated with the biochemistry of skin cancer cells within seconds, hence, providing immediate results. The cancer detection platform was developed by the BC Cancer Agency and the University of British Columbia and tested and refined at the Skin Care Centre at Vancouver General Hospital.
Verisante's top competitors include DermTech, DermaSensor and AMLo Biosciences.
Verisante offers Reverse Takeover Service and Capital Raising Assistance.
Yes, Verisante is publicly traded on TSXV under the ticker symbol VER.H.
Verisante operates through Verisante Technology, Inc..